Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
NCT04648826 · National Cancer Institute (NCI) · PHASE1/PHASE2 · withdrawn · last registry update 2021-12-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to notification from EMD Serono, for Bintrafusp alfa (M7824) regarding an observed increase in the frequently of early progression and death.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-12-12Results posted on the registry: AstraZeneca, Durvalumab + Placebo for Olaparib (NCT03775486)
- 2022-11-29Phase 3 first posted: AstraZeneca, Dato-DXd + Durvalumab (NCT05629585)
- 2022-08-01Phase 3 first posted: Georgetown University, Atezolizumab + Bevacizumab (NCT05482516)
- 2022-04-08Phase 3 first posted: InSightec, Pembrolizumab + Atezolizumab (NCT05317858)
- 2022-03-31Phase 3 first posted: AstraZeneca, Durvalumab (NCT05303532)
- 2022-03-31Phase 3 first posted: AstraZeneca, Tremelimumab + Durvalumab (NCT05301842)
- 2022-03-28Phase 3 first posted: Merck Sharp & Dohme LLC, pembrolizumab/vibostolimab + durvalumab (NCT05298423)
- 2022-02-24Phase 3 first posted: Leiden University Medical Center, Chemotherapy + Durvalumab (NCT05255653)
- 2022-02-09Results posted on the registry: Canadian Cancer Trials Group, Durvalumab + Tremelimumab (NCT03057106)
- 2022-02-03Phase 3 first posted: AstraZeneca, Durvalumab + Oleclumab (NCT05221840)
- 2022-01-27Phase 3 first posted: AstraZeneca, Durvalumab + Domvanalimab (NCT05211895)
- 2021-12-27Phase 3 first posted: Hoffmann-La Roche, Alectinib + Entrectinib (NCT05170204)
- 2021-11-09Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Bevacizumab (NCT05112965)
- 2021-10-26Phase 3 first posted: National Cancer Institute (NCI), Avelumab + Cabozantinib S-malate (NCT05092958)
- 2021-10-25Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Lurbinectedin (NCT05091567)
- 2021-10-01Phase 3 first posted: National Cancer Institute (NCI), Atezolizumab + Bevacizumab (NCT05063552)
- 2021-09-28Phase 3 first posted: National Cancer Institute (NCI), Atezolizumab + Carboplatin (NCT05058651)
- 2021-09-28Phase 3 first posted: Pfizer, Avelumab + Lorlatanib (NCT05059522)
- 2021-09-17Phase 3 first posted: Hoffmann-La Roche, Atezolizumab (NCT05047250)
- 2021-09-13Phase 3 first posted: AstraZeneca, savolitinib + durvalumab (NCT05043090)
- 2021-05-05Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Trastuzumab Emtansine (NCT04873362)
- 2021-01-15Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Becavizumab (NCT04712643)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision